Please assess the completion status of the following clinical trial:

Trial Title: Teplizumab for Prevention of Type 1 Diabetes In Relatives At-Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between ages of 8-45 years~* Have a relative with type 1 diabetes~* If first degree relative must be 8-45 years old (brother, sister, parent, offspring)~* If second degree relative must be between 8-20 years old (niece, nephew, aunt, uncle, grandchild, cousin)~* Abnormal glucose tolerance by OGTT confirmed with 7 weeks of baseline visit \[fasting blood glucose greater than 110mg/dL or and less than 126 mg/dL OR 2 hour glucose greater or equal to 140 mg/dL and less than 200 mg/dL OR 30, 60, or 90 minute value on OGTT greater than or equal to 200 mg/dL\]~* Presence of at least two confirmed diabetes autoantibodies~Exclusion Criteria:~* type 1 diabetes previously diagnosed or detected at screening \[fasting glucose greater or equal to 126 mg/dL or 2 hour glucose greater or equal to 200 mg/dL\]~* abnormalities in blood counts, liver enzymes, international normalised ratio (INR),~* positive purified protein derivative (PPD) test~  * vaccination with live virus within 6 weeks of randomization~* evidence of acute infection based on laboratory testing or clinical evidence~* serological evidence of past current or past HIV , hepatitis B, or hepatitis C infection~* Be currently pregnant or lactating~* Prior treatment with study drug~* Prior treatment with other monoclonal antibody in past one year

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- teplizumab (Type: ACTIVE_COMPARATOR): Intravenous infusions of teplizumab given for 14 consecutive days. Each infusion takes about 30 minutes and is followed by a 2 hour observation period.
- Placebo infusion (Type: PLACEBO_COMPARATOR): Intravenous infusion of placebo (saline) will be given for 14 consecutive days. Infusions will take approximately 30 minutes and will be followed by a two hour observation period.

Based on this trial design, predict the completion outcome and termination type (if applicable).